TY - JOUR
T1 - HDAC11 deficiency disrupts oncogene-induced hematopoiesis in myeloproliferative neoplasms
AU - Yue, Lanzhu
AU - Sharma, Vasundhara
AU - Horvat, Nathan P.
AU - Akuffo, Afua A.
AU - Beatty, Matthew S.
AU - Murdun, Cem
AU - Colin, Christelle
AU - Billington, Julia M.R.
AU - Goodheart, William E.
AU - Sahakian, Eva
AU - Zhang, Ling
AU - Powers, John J.
AU - Amin, Narmin E.
AU - Lambert-Showers, Que T.
AU - Darville, Lancia N.
AU - Pinilla-Ibarz, Javier
AU - Reuther, Gary W.
AU - Wright, Kenneth L.
AU - Conti, Chiara
AU - Lee, Jennifer Y.
AU - Zheng, Xiaozhang
AU - Ng, Pui Yee
AU - Martin, Matthew W.
AU - Marshall, C. Gary
AU - Koomen, John M.
AU - Levine, Ross L.
AU - Verma, Amit
AU - Grimes, H. Leighton
AU - Sotomayor, Eduardo M.
AU - Shao, Zonghong
AU - Epling-Burnette, Pearlie K.
N1 - Publisher Copyright:
© 2020 American Society of Hematology. All rights reserved.
PY - 2020/1/16
Y1 - 2020/1/16
N2 - Protein acetylation is an important contributor to cancer initiation. Histone deacetylase 6 (HDAC6) controls JAK2 translation and protein stability and has been implicated in JAK2- driven diseases best exemplified by myeloproliferative neoplasms (MPNs). By using novel classes of highly selective HDAC inhibitors and genetically deficient mouse models, we discovered that HDAC11 rather than HDAC6 is necessary for the proliferation and survival of oncogenic JAK2-driven MPN cells and patient samples. Notably, HDAC11 is variably expressed in primitive stem cells and is expressed largely upon lineage commitment. Although Hdac11 is dispensable for normal homeostatic hematopoietic stem and progenitor cell differentiation based on chimeric bone marrow reconstitution, Hdac11 deficiency significantly reduced the abnormal megakaryocyte population, improved splenic architecture, reduced fibrosis, and increased survival in the MPLW515L-MPN mouse model during primary and secondary transplantation. Therefore, inhibitors ofHDAC11 are an attractive therapy for treating patients with MPN. Although JAK2 inhibitor therapy provides substantial clinical benefit in MPN patients, the identification of alternative therapeutic targets is needed to reverse MPN pathogenesis and control malignant hematopoiesis. This study establishes HDAC11 as a unique type of target molecule that has therapeutic potential in MPN.
AB - Protein acetylation is an important contributor to cancer initiation. Histone deacetylase 6 (HDAC6) controls JAK2 translation and protein stability and has been implicated in JAK2- driven diseases best exemplified by myeloproliferative neoplasms (MPNs). By using novel classes of highly selective HDAC inhibitors and genetically deficient mouse models, we discovered that HDAC11 rather than HDAC6 is necessary for the proliferation and survival of oncogenic JAK2-driven MPN cells and patient samples. Notably, HDAC11 is variably expressed in primitive stem cells and is expressed largely upon lineage commitment. Although Hdac11 is dispensable for normal homeostatic hematopoietic stem and progenitor cell differentiation based on chimeric bone marrow reconstitution, Hdac11 deficiency significantly reduced the abnormal megakaryocyte population, improved splenic architecture, reduced fibrosis, and increased survival in the MPLW515L-MPN mouse model during primary and secondary transplantation. Therefore, inhibitors ofHDAC11 are an attractive therapy for treating patients with MPN. Although JAK2 inhibitor therapy provides substantial clinical benefit in MPN patients, the identification of alternative therapeutic targets is needed to reverse MPN pathogenesis and control malignant hematopoiesis. This study establishes HDAC11 as a unique type of target molecule that has therapeutic potential in MPN.
UR - http://www.scopus.com/inward/record.url?scp=85078504911&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85078504911&partnerID=8YFLogxK
U2 - 10.1182/blood.2019895326
DO - 10.1182/blood.2019895326
M3 - Article
C2 - 31750881
AN - SCOPUS:85078504911
SN - 0006-4971
VL - 135
SP - 191
EP - 207
JO - Blood
JF - Blood
IS - 3
ER -